Estimated two-year mortality rates with 95% confidence intervals were as follows (Figure 1): 13.1% (11.8%-14.6%) for patients prescribed both GLP-1 RA and SGLT2i 17.8% (16.6%-19.1%) for GLP-1 RA only 20.6% (19.5%-21.8%) for SGLT2i only 28.1% (27.7%-28.4%) for neither Prescription rates at the time of HF admission evolved as follows (Figure 2): January 2018: GLP-1 RA 0.9%, SGLT2i 0.5%, both 0.0%, neither 98.6% December 2024: GLP-1 RA 13.6%, SGLT2i 18.7%, both 6.3%, neither 74.0%
Well-tolerated by most patients: While some people experience mild, temporary gastrointestinal effects like nausea, most find these side effects diminish as their body adjusts to the medication
There is no universal "best" site for weight loss or medication absorption
But without smart supplementation, it risks leaving you deficient, tired, and underperforming
And use the 60-day window the way it's designed to be used
Protein-rich foods are incredibly satiating